Medicinova (MNOV) Announces Acceptance of MN-166 ALS Abstract for Presentation at Upcoming ALS/MND Symposium

October 31, 2016 6:30 AM EDT
Get Alerts MNOV Hot Sheet
Trade MNOV Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

MediciNova, Inc. (Nasdaq: MNOV) announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS has been accepted for oral presentation at the 27th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held December 7-9, 2016 in Dublin, Ireland.

The presentation entitled "Adaptive Design Single Centre Phosphodiesterase Type 4 (PDE-4) Inhibitor [MN-166 (Ibudilast)] Phase 1b/2a Clinical Trial Double Blind with Open Label Extension for ALS Patients: Interim-blinded Analysis, Behaviour of Creatinine as a Biomarker in Short Clinical Trials [NCT02238626]" will be given by Principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center.

Presentation details are as follows:

Session Date and Time: Friday, December 9, 2016, 8:50 – 9:10 am

Session: Clinical Trials

Location: Convention Center Dublin (CCD), Spencer Dock, North Wall Quay, Dublin 1, Ireland

About the ALS Trial

MediciNova, in collaboration with Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, is currently evaluating MN-166 (ibudilast) in both early and advanced stage ALS patients. This ongoing trial is a randomized, double-blind, placebo-controlled study which includes a six-month treatment period followed by a six-month open-label extension. The study is evaluating several efficacy endpoints including functional activity (ALSFRS-R), respiratory function and muscle strength in subjects with ALS. The study is configured to enroll up to 60 ALS patients without NIV (Non-Invasive Ventilator) and up to 60 ALS patients with NIV.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment